Mouse study maps key brain targets for Dravet gene therapy

Reducing defective protein in hippocampus cuts seizure risk, researchers find

Written by Marisa Wexler, MS |

A mouse stands looking out of a glass box.

A mouse study sheds light on considerations for gene therapies. (Photo by iStock)

Gene therapy to restore activity of the defective NaV1.1 protein in a specific region of the brain — the hippocampus — is sufficient to reduce seizure risk in Dravet syndrome, according to a mouse study.

The findings indicate that seizure risk may be further reduced with gene therapy that targets the hippocampus along with the thalamus and overlying cortical regions. While hippocampus-only gene therapy did not improve survival in this mouse model, the approach targeting the hippocampus alongside other regions was shown to reduce the risk of seizure-related death.

“In our experiments, hippocampal restoration alone produced a substantial therapeutic benefit, whereas broader targeting of the hippocampus, thalamus, and cortex provided additional improvements in seizure burden and survival,” the researchers wrote.

Together, the findings suggest that gene therapy targeting the hippocampus may offer some benefit for Dravet patients, but to achieve the best results, it will likely be necessary to develop therapies that can effectively target cells across many brain regions.

The study, “Adeno-associated virus-mediated restoration of NaV1.1 in targeted brain regions ameliorates epilepsy in symptomatic Dravet syndrome mice,” was published in Epilepsia.

Recommended Reading
new column banner

Resetting the clock on my daughter’s stretch of seizure freedom

Gene therapy as a treatment

Dravet syndrome is caused mainly by mutations in the SCN1A gene, which provides instructions to make part of the NaV1.1 protein. A lack of functional NaV1.1 disrupts nerve cell activity in the brain, resulting in seizures and other Dravet symptoms.

Gene therapy for Dravet syndrome is an investigational approach that aims to deliver a functional version of the SCN1A gene to nerve cells in the brain, restoring NaV1.1 and normalizing neural signaling. But even though cells throughout the brain lack NaV1.1 in Dravet, not all brain cells are affected equally by the disease. Previous research has suggested that deficiency of NaV1.1 in the hippocampus, a small brain region that’s key for memory, is sufficient to trigger seizures in mice.

The researchers wondered: If deficiency of NaV1.1 in the hippocampus is enough to trigger seizures, might restoring NaV1.1 activity in this brain region alone reduce seizures in mice with Dravet syndrome?

To find out, they conducted a series of tests using a mouse model of Dravet in which the Scn1a gene is silenced. The mice were treated with a gene therapy approach that uses a modified virus to deliver a molecular tool that switches the mice’s own Scn1a gene back on. To deliver this therapy specifically to the hippocampus, the mice underwent a surgical procedure in which the scientists carefully injected a small amount of the viral vector into this region alone. Analyses of brain tissue from the mice confirmed that this approach restored NaV1.1 protein levels in the hippocampus, but not in other brain regions.

Results indicated that gene therapy targeting the hippocampus reduced seizure risk. Over about two weeks of monitoring, 90% of untreated mice experienced at least one generalized tonic-clonic seizure, but these seizures were detected in fewer than half of mice given hippocampus-targeted gene therapy. However, gene therapy of the hippocampus alone did not substantially improve survival.

The researchers then ran tests in which they administered gene therapy to the hippocampus, thalamus, and overlying cortical regions, which are other parts of the brain implicated in Dravet syndrome. These mice similarly showed a significant reduction in seizure frequency, but they also had significantly better survival outcomes and a lower risk of seizure-related mortality.

“Compared with hippocampal targeting alone, multiregion restoration was associated with improved survival and trends toward greater reductions in seizure burden,” the researchers wrote.

The findings may have important implications for the development of gene therapies for people with Dravet, the researchers said. Although targeting small, well-defined regions like the hippocampus may be easier than targeting multiple brain regions at once, the data suggest that targeting multiple regions may yield greater benefit than more limited targeting.

“The limited efficacy of regional correction compared with systemic gene restoration indicates that the chronic phase of [Dravet] is sustained by dysfunction across distributed neuronal networks,” the scientists wrote. “These results support the development of therapeutic strategies capable of achieving broad circuit-wide restoration of Scn1a expression.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.